This study demonstrates how ascorbic acid improves collagen and extracellular matrix in glucocorticoid-induced osteoporosis, suggesting therapeutic benefits.
Osteoporosis is a prevalent skeletal disorder characterized by decreased bone mass and structural deterioration, leading to an increased risk of fractures. This study focuses on the regulatory role of Vitamin C (ascorbic acid; AA) in the context of glucocorticoid‐induced osteoporosis (GIOP), which results from long‐term glucocorticoid (GC) therapy. The data showed that GCs impair AA metabolism in osteoblasts, thereby disrupting collagen synthesis and compromising extracellular matrix (ECM) integrity. Notably, AA integration in the collagen matrix improved its biochemical and mechanical properties. Additionally, it has been shown that the presence of AA restored osteoblast and endothelial function, enhanced collagen production, and improved endothelial barrier function under GC exposure. These results underscore the critical role of Vitamin C in bone matrix maintenance and homeostasis. Collectively, this work highlights the therapeutic potential of Vitamin C as a supportive treatment to counteract the deleterious skeletal effects of long‐term GC therapy.
No takes yet. Share an insight, caveat, or question.
Curtis et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: